Last reviewed · How we verify

NCT04519190

Screening for Atrial Fibrillation With Prolonged Continuous Single-lead ECG Devices in High-risk Patients

Status unknown Last updated 19 August 2020
What this trial tests

trial testing Prolonged continuous single-lead ECG monitor in Atrial Fibrillation in 300 participants. Status unknown.

Timeline
25 August 2020
Primary endpoint
31 August 2023
31 August 2023

Quick facts

Lead sponsorHuashan Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment300
Start date25 August 2020
Primary completion31 August 2023
Estimated completion31 August 2023

Drugs / interventions tested

Conditions studied

Sponsor

Huashan Hospital

Who can join

Adults 18 to 85, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Atrial fibrillation(AF) can be asymptomatic and thus left unidentified in many people, but holds potential risk of lethal complications such as stroke and congestive heart failure. With different screening strategy, the screening result will be different. The longer the monitoring period is, the higher chances AF episodes can be identified, but with greater cost and lower compliance. Therefore, in this study, the investigators want to find the most cost-effective method for AF screening in high risk population with prolonged continuous single-lead ECG device.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Atrial fibrillation: epidemiology, screening and digital health.
    Linz D, Gawalko M, Betz K, Hendriks JM, et al · · 2024 · cited 230× · PMID 38362546 · DOI 10.1016/j.lanepe.2023.100786

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Huashan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04519190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing